COVID-19 (Coronavirus) Update: Testing and Information | Vaccine Updates | Visitor Guidelines

AGAVE-201, A Phase 2, open-label, Randomized, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of Axatilimab at 3 Different Doses in Patient with Recurrent or Refractory Active Chronic Graft Versus Host Disease who have Received at Least 2 lines of Systemic Therapy.

Protocol No
SYNDAX-SNDX-6352-0504-CGVHD
Principal Investigator
Saurabh Chhabra
Phase
II
Summary
This project is being done to compare how well axatilimab helps Chronic Graft Versus Host Disease at different dose levels and to find out whether there are side effects from its use.
Description
Phase 2 Study of Axatilimab at 3 Different Doses in Patients with Chronic Graft Versus Host Disease.
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL